A review of sevelamer Hydrochloride in end-stage renal disease patients on Dialysis

Clinical Medicine Insights: Therapeutics

Volumn 3, Issue , 2011, Pages 51-55

  Spasovski, Goce ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Calcium based binders; Hyperphosphatemia; KDIGO guidelines; KDOQI guidelines; Non calcium based binders; Sevelamer

Indexed keywords

CALCIUM ACETATE; CALCIUM BASED PHOSPHATE BINDER; CALCIUM CARBONATE; MAGNESIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; DRUG RESPONSE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

EID: 79953017665     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S5990     Document Type: Review

References (40)

1. Vanholder R, Massy Z, Argiles A, Spasovski G, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048-56.
2. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-80.
3. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-18.
4. Vanholder R, Abou-Deif O, Argiles A, et al. The role of EUTox in uremic toxin research. Semin Dial. 2009;22(4):323-8.
5. Moe S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-53.
6. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial. 2009;22(4):357-62.
7. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305-15.
8. Cancela AL, Oliveira RB, Graciolli FG, et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2010;117(1):c74-82.
9. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant. 2008;24:948-55.
10. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-92.
11. Liu S, Gupta A, Quarles SO. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens. 2007;16(4):329-35.
12. Spasovski G. New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease. Recent Patents Cardiovasc Drug Discov. 2008;3(3):222-8.
13. Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol. 2007;39(4):1209-16.
14. Goodman WG, Goldin SJ, Kuizon BD. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-83.
15. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731-40.
16. Gelev S, Spasovski G, Trajkovski Z, et al. Factors associated with various arterial calcifications in haemodialysis patients. Prilozi. 2008;29(2):185-99.
17. National Kidney Foundation. K/DOQI, NKF: clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-201.
18. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33(4):694-701.
19. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46:855-61.
20. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-52.
21. Zoccali C, Abramowicz D, Cannata -Andia JB, et al. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrol Dial Transplant. 2008;23:2162-6.
22. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Kidney Int Suppl. 2009;(113):S1-130.
23. Farkouh ME, Fuster V. Meta -analysis of small trials: proceed with caution. Nat Clin Pract Nephrol. 2008;4:115.
24. Tonelli M, Wiebe N, Culleton B, et al. Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22:2856-66.
25. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22(10):2867-78.
26. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438-41.
27. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium- based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-7.
28. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51(3):445-54.
29. Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405-12.
30. Assimon MM, Mousa S, Shaker O, Pai AB. The effect of sevelamer hydrochloride and Calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. Consult Pharm. 2010;25(1):41-54.
31. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non- calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24(10):3168-74.
32. Shantouf R, Ahmadi N, Flores F, et al. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol. 2010;74(1):12-8.
33. Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25(8):2672-9.
34. Zhang Q, Li M, Lu Y, et al. Meta-analysis comparing sevelamer and calcium- based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract. 2010;115(4):c259-67.
35. Fishbane S, Delmez J, Suki WN, et al. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis. 2010;55(2):307-15.
36. De Francisco AL, Leidig M, Covic A, et al. Evaluation of calcium acetate/ magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25:3707-17.
37. Spasovski G, Vanholder R. Is combined calcium/magnesium phosphate binder really non-inferior to sevelamer hydrochloride? Nephrol Dial Transplant. In press 2011.
38. Negri AL. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? J Nephrol. 2010;23(6):653-7.
39. Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007; 22:2867-78.
40. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007;71:312-7.